These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 27807285)

  • 1. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
    Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
    Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
    Forman M; Palcza J; Tseng J; Stone JA; Walker B; Swearingen D; Troyer MD; Dockendorf MF
    Clin Transl Sci; 2019 Sep; 12(5):545-555. PubMed ID: 31215755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis.
    Saravanan K; Sivanandam M; Hunday G; Mathiyalagan L; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2339-2354. PubMed ID: 30044206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
    Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW
    J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
    Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
    J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
    Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
    Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
    Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
    J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
    Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
    J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
    Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
    J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
    Andrew RJ; Fernandez CG; Stanley M; Jiang H; Nguyen P; Rice RC; Buggia-Prévot V; De Rossi P; Vetrivel KS; Lamb R; Argemi A; Allaert ES; Rathbun EM; Krause SV; Wagner SL; Parent AT; Holtzman DM; Thinakaran G
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9665-E9674. PubMed ID: 29078331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
    Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
    Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.